SHL Telemedicine - SHLT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 97.31%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.58
▼ -0.25 (-4.29%)

This chart shows the closing price for SHLT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SHL Telemedicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SHLT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHLT

Analyst Price Target is $11.00
▲ +97.31% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for SHL Telemedicine in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 97.31% upside from the last price of $5.58.

This chart shows the closing price for SHLT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in SHL Telemedicine. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2024Litchfield Hills ResearchReiterated RatingBuy$11.00Low
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
SHL Telemedicine logo
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. It offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. The company serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was founded in 1987 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $5.58
Low: $5.52
High: $5.76

50 Day Range

MA: $6.24
Low: $5.57
High: $7.09

52 Week Range

Now: $5.58
Low: $5.52
High: $12.75

Volume

1,123 shs

Average Volume

6,364 shs

Market Capitalization

$81.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SHL Telemedicine?

The following Wall Street analysts have issued research reports on SHL Telemedicine in the last year: Litchfield Hills Research.
View the latest analyst ratings for SHLT.

What is the current price target for SHL Telemedicine?

1 Wall Street analysts have set twelve-month price targets for SHL Telemedicine in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 97.3%. Litchfield Hills Research has the highest price target set, predicting SHLT will reach $11.00 in the next twelve months. Litchfield Hills Research has the lowest price target set, forecasting a price of $11.00 for SHL Telemedicine in the next year.
View the latest price targets for SHLT.

What is the current consensus analyst rating for SHL Telemedicine?

SHL Telemedicine currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SHLT will outperform the market and that investors should add to their positions of SHL Telemedicine.
View the latest ratings for SHLT.

What other companies compete with SHL Telemedicine?

How do I contact SHL Telemedicine's investor relations team?

The company's listed phone number is 972-3-561-2212 and its investor relations email address is [email protected]. The official website for SHL Telemedicine is www.shl-telemedicine.com. Learn More about contacing SHL Telemedicine investor relations.